Breaking news

China Takes Legal Action Against EU Over Electric Vehicle Tariff Hike

China has launched a legal dispute against the European Union (EU) at the World Trade Organization (WTO) in response to the EU’s decision to raise import tariffs on Chinese electric vehicles (EVs). The case comes on the heels of an EU investigation that concluded Chinese carmakers benefit from state subsidies, giving them an unfair edge in the European market.

Key Details:

  1. WTO Complaint: China’s filing marks its second WTO challenge over higher tariffs, with the complaint aiming to address the EU’s determination that Chinese EV manufacturers benefit from unfair government support.
  2. Impact on Chinese Car Makers: The new EU tariffs range from 17% for BYD, 18.8% for Geely (Volvo’s parent company), to a significant 35.3% for SAIC Motor Corp, making it one of the most heavily affected companies.
  3. WTO Dispute Timeline: Under WTO dispute settlement rules, China and the EU have 60 days to negotiate a resolution. If unresolved, the case may proceed to a WTO panel ruling. However, the WTO’s highest appellate body remains inactive due to a shortage of judges, potentially complicating the resolution process.

The heightened tariffs, which took effect on November 1, reflect growing trade friction between Brussels and Beijing. EU officials argue that China’s subsidies and access to inexpensive raw materials have granted Chinese EV companies excessive leverage over European competitors. In response, Brussels is exploring solutions, such as adjusting price commitments, to address these market imbalances while upholding WTO principles.

Negotiations between the EU and Chinese officials are expected to intensify in the coming weeks, with an EU delegation likely to travel to China to pursue a compromise. Both sides aim to foster fair market conditions while respecting WTO guidelines.

AI Expands Role In Consumer Healthcare And Drug Development

Artificial intelligence is increasingly used in consumer healthcare to manage personal data and support health-related decisions. Use cases range from administrative tasks, such as appointment scheduling and note-taking, to handling basic health queries. As these tools become more accessible, industry participants are encouraging broader use beyond routine functions.

AI As A Personal Health Advisor

The development of AI tools is extending into everyday health support. Alex Zhavoronkov, CEO of Insilico Medicine, said consumers can use AI systems to address routine health-related questions. Speaking at CNBC’s CONVERGE LIVE event in Singapore, he noted that some AI tools are capable of handling basic inquiries, allowing medical professionals to focus on more complex cases.

Major Tech Players Enter The Health Arena

At the same time, large technology companies are expanding into consumer health applications. OpenAI introduced ChatGPT Health, a platform that connects medical records and wellness applications to an AI interface. Similarly, Amazon launched HealthAI for users of One Medical, offering analysis of medical records, laboratory results, and current medications.

Balancing Innovation And Caution

As adoption increases, industry representatives are highlighting the need for oversight. Shreehas Tambe, CEO and Managing Director of Biocon, said that reliance on advanced systems without sufficient familiarity may introduce risks. He added that expert review remains necessary, particularly in areas such as drug development and clinical validation.

Revolutionizing Drug Discovery

Beyond consumer applications, AI is also reshaping pharmaceutical research. Development timelines for drug candidates can be reduced from more than four years to around 18 months. This shift is reflected in a $2.75 billion collaboration between Eli Lilly and Insilico Medicine, highlighting continued investment in AI-driven drug discovery.

Aretilaw firm
eCredo
The Future Forbes Realty Global Properties
Uol

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter